Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
This invention relates to novel chromen-2-one derivatives of Formula (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
1. A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein
Q represents a 3-chromen-2-one-yl group substituted with a furanyl or a benzofuranyl group; and
R 1 represents hydrogen or alkyl.
2. The chemical compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein R 1 represents hydrogen or alkyl.
3. The chemical compound of claim 1 , which is exo-7-[(1S,3S,5R)-(8-Aza-bicyclo[3.2.1]oct-3-yl)oxy]-3-furan-2-yl-chromen-2-one; exo-7-[(1S,3S,5R)-(8-Aza-bicyclo[3.2.1]oct-3-yl)oxy]-3-furan-3-yl-chromen-2-one; or exo-7-[(1S,3S,5R)-(8-Aza-bicyclo[3.2.1]oct-3-yl)oxy]-3-benzofuran-2-yl-chromen-2-one;
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition, comprising a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.